Base de dados : MEDLINE
Pesquisa : D01.045.250.050 [Categoria DeCS]
Referências encontradas : 3321 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 333 ir para página                         

  1 / 3321 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:28464026
[Au] Autor:Diemert DJ; Freire J; Valente V; Fraga CG; Talles F; Grahek S; Campbell D; Jariwala A; Periago MV; Enk M; Gazzinelli MF; Bottazzi ME; Hamilton R; Brelsford J; Yakovleva A; Li G; Peng J; Correa-Oliveira R; Hotez P; Bethony J
[Ad] Endereço:Department of Microbiology, Immunology and Tropical Medicine, School of Medicine and Health Sciences, The George Washington University, Washington DC, United States of America.
[Ti] Título:Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults.
[So] Source:PLoS Negl Trop Dis;11(5):e0005574, 2017 05.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Necator americanus Glutathione-S-Transferase-1 (Na-GST-1) plays a role in the digestion of host hemoglobin by adult N. americanus hookworms. Vaccination of laboratory animals with recombinant Na-GST-1 is associated with significant protection from challenge infection. Recombinant Na-GST-1 was expressed in Pichia pastoris and adsorbed to aluminum hydroxide adjuvant (Alhydrogel) according to current Good Manufacturing Practice. Two Phase 1 trials were conducted in 142 healthy adult volunteers in the United States and Brazil, first in hookworm-naïve individuals and then in residents of a N. americanus endemic area in Brazil. Volunteers received one of three doses of recombinant Na-GST-1 (10, 30, or 100 µg) adjuvanted with Alhydrogel, adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl Lipid A (GLA-AF), or the hepatitis B vaccine. Vaccinations were administered via intramuscular injection on days 0, 56, and 112. Na-GST-1/Alhydrogel was well tolerated in both hookworm-naïve and hookworm-exposed adults, with the most common adverse events being mild to moderate injection site pain and tenderness, and mild headache and nausea; no vaccine-related severe or serious adverse events were observed. Antigen-specific IgG antibodies were induced in a dose-dependent fashion, with increasing levels observed after each vaccination in both trials. The addition of GLA-AF to Na-GST-1/Alhydrogel did not result in significant increases in specific IgG responses. In both the US and Brazil studies, the predominant IgG subclass induced against Na-GST-1 was IgG1, with lesser amounts of IgG3. Vaccination of both hookworm-naïve and hookworm-exposed adults with recombinant Na-GST-1 was safe, well tolerated, and resulted in significant antigen-specific IgG responses. Based on these results, this vaccine will be advanced into clinical trials in children and eventual efficacy studies. TRIAL REGISTRATION: ClinicalTrials.gov (NCT01261130 for the Brazil trial and NCT01385189 for the US trial).
[Mh] Termos MeSH primário: Ancylostomatoidea/imunologia
Antígenos de Helmintos/imunologia
Glutationa Transferase/imunologia
Infecções por Uncinaria/prevenção & controle
Vacinas Sintéticas/imunologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/administração & dosagem
Adolescente
Adulto
Hidróxido de Alumínio/administração & dosagem
Animais
Anticorpos Anti-Helmínticos/sangue
Brasil
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/patologia
Feminino
Glucosídeos/administração & dosagem
Voluntários Saudáveis
Vacinas contra Hepatite B/administração & dosagem
Infecções por Uncinaria/imunologia
Seres Humanos
Imunoglobulina G/sangue
Injeções Intramusculares
Lipídeo A/administração & dosagem
Masculino
Meia-Idade
Resultado do Tratamento
Estados Unidos
Vacinas Sintéticas/administração & dosagem
Vacinas Sintéticas/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Helminth); 0 (Antigens, Helminth); 0 (Glucosides); 0 (Hepatitis B Vaccines); 0 (Immunoglobulin G); 0 (Lipid A); 0 (Vaccines, Synthetic); 0 (glucopyranosyl lipid-A); 5QB0T2IUN0 (Aluminum Hydroxide); EC 2.5.1.18 (Glutathione Transferase)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0005574


  2 / 3321 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28454674
[Au] Autor:Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
[Ad] Endereço:Hospital Maternidad Nuestra Señora de la Altagracia, Santo Domingo, Dominican Republic.
[Ti] Título:Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
[So] Source:Lancet Infect Dis;17(7):745-753, 2017 Jul.
[Is] ISSN:1474-4457
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cost and supply constraints are key challenges in the use of inactivated polio vaccine (IPV). Dose reduction through adsorption to aluminium hydroxide (Al) is a promising option, and establishing its effectiveness in the target population is a crucial milestone in developing IPV-Al. The aim of this clinical trial was to show the non-inferiority of three IPV-Al vaccines to standard IPV. METHODS: In this phase 2, non-inferiority, observer-blinded, randomised, controlled, single-centre trial in the Dominican Republic, healthy infants aged 6 weeks, not previously polio vaccinated, were allocated after computer-generated randomisation by block-size of four, to receive one of four IPV formulations (three-times reduced dose [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly in the thigh at 6, 10, and 14 weeks of age. The primary outcome was seroconversion for poliovirus types 1, 2, and 3 with titres more than or equal to four-fold higher than the estimated maternal antibody titre and more than or equal to 8 after three vaccinations. Non-inferiority was concluded if the lower two-sided 90% CI of the seroconversion rate difference between IPV-Al and IPV was greater than -10%. The safety analyses were based on the safety analysis set (randomly assigned participants who received at least one trial vaccination) and the immunogenicity analyses were based on the per-protocol population. This study is registered with ClinicalTrials.gov registration, number NCT02347423. FINDINGS: Between Feb 2, 2015, and Sept 26, 2015, we recruited 824 infants. The per-protocol population included 820 infants; 205 were randomly assigned to receive 1/3 IPV-Al, 205 to receive 1/5 IPV-Al, 204 to receive 1/10 IPV-Al, and 206 to receive IPV. The proportion of individuals meeting the primary endpoint of seroconversion for poliovirus types 1, 2, and 3 was already high for the three IPV-Al vaccines after two vaccinations, but was higher after three vaccinations (ie, after completion of the expanded programme of immunisation schedule): 1/3 IPV-Al 98·5% (n=202, type 1), 97·6% (n=200; type 2), and 99·5% (n=204, type 3); 1/5 IPV-Al: 99·5% (n=204, type 1), 96·1% (n=197, type 2), and 98·5% (n=202, type 3); and 1/10 IPV-Al: 98·5% (n=201, type 1), 94·6% (n=193, type 2), and 99·5% (n=203, type 3). All three IPV-Al were non-inferior to IPV, with absolute differences in percentage seroconversion for each poliovirus type being greater than -10% (1/3 IPV-Al type 1, -1·46 [-3·60 to 0·10], type 2, -0·98 [-3·62 to 1·49], and type 3, -0·49 [-2·16 to 0·86]; 1/5 IPV-Al type 1, -0·49 [-2·16 to 0·86], type 2, -2·45 [-5·47 to 0·27], and type 3, -1·46 [-3·60 to 0·10]; and 1/10 IPV-Al type 1, -1·47 [-3·62 to 0·10], type 2, -3·94 [-7·28 to -0·97], and type 3, -0·49 [-2·17 to 0·86]). Three serious adverse events occurred that were unrelated to the vaccine. INTERPRETATION: The lowest dose (1/10 IPV-Al) of the vaccine performed well both after two and three doses. Based on these results, this new vaccine is under investigation in phase 3 trials. FUNDING: Bill & Melinda Gates Foundation.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/administração & dosagem
Hidróxido de Alumínio
Esquemas de Imunização
Imunogenicidade da Vacina
Poliomielite/prevenção & controle
Vacina Antipólio de Vírus Inativado/administração & dosagem
Vacina Antipólio Oral/administração & dosagem
[Mh] Termos MeSH secundário: Anticorpos Antivirais/sangue
Anticorpos Antivirais/imunologia
República Dominicana
Feminino
Seres Humanos
Lactente
Masculino
Poliovirus/efeitos dos fármacos
Poliovirus/imunologia
Vacinação/métodos
Eliminação de Partículas Virais
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Viral); 0 (Poliovirus Vaccine, Inactivated); 0 (Poliovirus Vaccine, Oral); 5QB0T2IUN0 (Aluminum Hydroxide)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180121
[Lr] Data última revisão:
180121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  3 / 3321 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28836872
[Au] Autor:Dettmar PW; Gil-Gonzalez D; Fisher J; Flint L; Rainforth D; Moreno-Herrera A; Potts M
[Ad] Endereço:a Research Department , Technostics Limited, Castle Hill Hospital , Cottingham , UK.
[Ti] Título:A comparative study on the raft chemical properties of various alginate antacid raft-forming products.
[So] Source:Drug Dev Ind Pharm;44(1):30-39, 2018 Jan.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Research to measure the chemical characterization of alginate rafts for good raft performance and ascertain how formulation can affect chemical parameters. SIGNIFICANCE: A selection of alginate formulations was investigated all claiming to be proficient raft formers with significance between products established and ranked. METHODS: Procedures were selected which demonstrated the chemical characterization allowing rafts to effectively impede the reflux into the esophagus or in severe cases to be refluxed preferentially into the esophagus and exert a demulcent effect, with focus of current research on methods which complement previous studies centered on physical properties. The alginate content was analyzed by a newly developed HPLC method. Methods were used to determine the neutralization profile and the acid neutralization within the raft determined along with how raft structure affects neutralization. RESULTS: Alginate content of Gaviscon Double Action (GDA) within the raft was significantly superior (p < .0001) to all competitor products. The two products with the highest raft acid neutralization capacity were GDA and Rennie Duo, the latter product not being a raft former. Raft structure was key and GDA had the right level of porosity to allow for longer duration of neutralization. CONCLUSION: Alginate formulations require three chemical reactions to take place simultaneously: transformation to alginic acid, sodium carbonate reacting to form carbon dioxide, calcium releasing free calcium ions to bind with alginic acid providing strength to raft formation. GDA was significantly superior (p <.0001) to all other comparators.
[Mh] Termos MeSH primário: Alginatos/química
Hidróxido de Alumínio/química
Antiácidos/química
Carbonato de Cálcio/química
Carbonatos/química
Esôfago/química
Refluxo Gastroesofágico/tratamento farmacológico
Magnésio/química
Ácido Silícico/química
Bicarbonato de Sódio/química
[Mh] Termos MeSH secundário: Alginatos/farmacologia
Alginatos/uso terapêutico
Antiácidos/metabolismo
Antiácidos/uso terapêutico
Combinação de Medicamentos
Impedância Elétrica
Refluxo Gastroesofágico/metabolismo
Ácido Glucurônico/química
Ácido Glucurônico/farmacologia
Ácido Glucurônico/uso terapêutico
Ácidos Hexurônicos/química
Ácidos Hexurônicos/farmacologia
Ácidos Hexurônicos/uso terapêutico
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alginates); 0 (Antacids); 0 (Carbonates); 0 (Drug Combinations); 0 (Hexuronic Acids); 1343-98-2 (Silicic Acid); 45P3261C7T (sodium carbonate); 5QB0T2IUN0 (Aluminum Hydroxide); 66220-44-8 (alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination); 82351-35-7 (Rennie); 8A5D83Q4RW (Glucuronic Acid); 8C3Z4148WZ (alginic acid); 8MDF5V39QO (Sodium Bicarbonate); H0G9379FGK (Calcium Carbonate); I38ZP9992A (Magnesium)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170825
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1371737


  4 / 3321 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29202404
[Au] Autor:Zhu W; Liu X; Wang Y; Tong Y; Hu Y
[Ad] Endereço:Zhejiang Academy of Traditional Chinese Medicine, Hangzhou 310007, China; ZJU-ENS Joint Laboratory of Medicinal Chemistry, Zhejiang University, Hangzhou 310058, China.
[Ti] Título:Discovery of a novel series of α-terpineol derivatives as promising anti-asthmatic agents: Their design, synthesis, and biological evaluation.
[So] Source:Eur J Med Chem;143:419-425, 2018 Jan 01.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:A series of novel α-terpineol derivatives were designed and synthesized through structural derivatization of the tertiary hydroxyl moiety or reduction of the double bond. Of the resulting compounds, eight compounds enhanced relaxation of airway smooth muscle (ASM) compared to the α-terpineol precursor, and four compounds (4a, 4d, 4e, and 4i)were superior or comparable to aminophylline at a concentration of 0.75 mmol/L. Assays for 3'-5'-Cyclic adenosine monophpsphate (cAMP) activation revealed that some representative α-terpineol derivatives in this series were capable of upregulating the level of cAMP in ASM cells. Further in vivo investigation using the asthmatic rat model, illustrated that treatment with the compounds 4a and 4e resulted in significantly lowered lung resistance (RL) and enhanced dynamic lung compliance (Cldyn), two important parameters for lung fuction. Moreover, treatment with 4e downregulated the levels of both IL-4 and IL-17. Due to its several favorable physiological functions, including ASM relaxation activity, cAMP activation capability, and in vivo anti-asthmatic efficacy, 4e is a promising remedy for bronchial asthma, meriting extensive development.
[Mh] Termos MeSH primário: Antiasmáticos/uso terapêutico
Asma/tratamento farmacológico
Cicloexenos/uso terapêutico
Descoberta de Drogas
Monoterpenos/uso terapêutico
[Mh] Termos MeSH secundário: Administração Oral
Hidróxido de Alumínio/administração & dosagem
Animais
Antiasmáticos/administração & dosagem
Antiasmáticos/química
Asma/induzido quimicamente
Cicloexenos/administração & dosagem
Cicloexenos/química
Relação Dose-Resposta a Droga
Cobaias
Injeções Intraperitoneais
Masculino
Estrutura Molecular
Monoterpenos/administração & dosagem
Monoterpenos/química
Ovalbumina/administração & dosagem
Ratos
Ratos Sprague-Dawley
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Asthmatic Agents); 0 (Cyclohexenes); 0 (Monoterpenes); 21334LVV8W (alpha-terpineol); 5QB0T2IUN0 (Aluminum Hydroxide); 9006-59-1 (Ovalbumin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180101
[Lr] Data última revisão:
180101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE


  5 / 3321 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29211241
[Au] Autor:Cunha CEPD; Moreira C; Rocha ADSR; Finger PF; Magalhães CG; Ferreira MRA; Dellagostin OA; Moreira ÂN; Conceição FR
[Ad] Endereço:Universidade Federal de Pelotas, Centro de Desenvolvimento Tecnológico, Biotecnologia, Pelotas, RS, Brasil.
[Ti] Título:Parenteral adjuvant potential of recombinant B subunit of Escherichia coli heat-labile enterotoxin.
[So] Source:Mem Inst Oswaldo Cruz;112(12):812-816, 2017 Dec.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The B subunit of Escherichia coli heat-labile enterotoxin (LTB) is a potent mucosal immune adjuvant. However, there is little information about LTB's potential as a parenteral adjuvant. OBJECTIVES: We aimed at evaluating and better understanding rLTB's potential as a parenteral adjuvant using the fused R1 repeat of Mycoplasma hyopneumoniae P97 adhesin as an antigen to characterise the humoral immune response induced by this construct and comparing it to that generated when aluminium hydroxide is used as adjuvant instead. METHODS: BALB/c mice were immunised intraperitoneally with either rLTBR1 or recombinant R1 adsorbed onto aluminium hydroxide. The levels of systemic anti-rR1 antibodies (total Ig, IgG1, IgG2a, and IgA) were assessed by enzyme-linked immunosorbent assay (ELISA). The ratio of IgG1 and IgG2a was used to characterise a Th1, Th2, or mixed Th1/Th2 immune response. FINDINGS: Western blot confirmed rR1, either alone or fused to LTB, remained antigenic; anti-cholera toxin ELISA confirmed that LTB retained its activity when expressed in a heterologous system. Mice immunised with the rLTBR1 fusion protein produced approximately twice as much anti-rR1 immunoglobulins as mice vaccinated with rR1 adsorbed onto aluminium hydroxide. Animals vaccinated with either rLTBR1 or rR1 adsorbed onto aluminium hydroxide presented a mixed Th1/Th2 immune response. We speculate this might be a result of rR1 immune modulation rather than adjuvant modulation. Mice immunised with rLTBR1 produced approximately 1.5-fold more serum IgA than animals immunised with rR1 and aluminium hydroxide. MAIN CONCLUSIONS: The results suggest that rLTB is a more powerful parenteral adjuvant than aluminium hydroxide when administered intraperitoneally as it induced higher antibody titres. Therefore, we recommend that rLTB be considered an alternative adjuvant, even if different administration routes are employed.
[Mh] Termos MeSH primário: Adesinas Bacterianas/imunologia
Adjuvantes Imunológicos/administração & dosagem
Toxinas Bacterianas/administração & dosagem
Enterotoxinas/administração & dosagem
Proteínas de Escherichia coli/administração & dosagem
Mycoplasma hyopneumoniae/imunologia
Pneumonia Suína Micoplasmática/prevenção & controle
[Mh] Termos MeSH secundário: Hidróxido de Alumínio
Animais
Toxinas Bacterianas/imunologia
Enterotoxinas/imunologia
Ensaio de Imunoadsorção Enzimática
Proteínas de Escherichia coli/imunologia
Feminino
Camundongos
Camundongos Endogâmicos BALB C
Pneumonia Suína Micoplasmática/imunologia
Suínos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adhesins, Bacterial); 0 (Adjuvants, Immunologic); 0 (Bacterial Toxins); 0 (Enterotoxins); 0 (Escherichia coli Proteins); 0 (P97 protein, Mycoplasma); 0 (heat-labile enterotoxin, E coli); 5QB0T2IUN0 (Aluminum Hydroxide)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171227
[Lr] Data última revisão:
171227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171207
[St] Status:MEDLINE


  6 / 3321 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464343
[Au] Autor:Coyle C; Crawford G; Wilkinson J; Thomas SJ; Bytzer P
[Ad] Endereço:RB, Slough, Berkshire, UK.
[Ti] Título:Randomised clinical trial: addition of alginate-antacid (Gaviscon Double Action) to proton pump inhibitor therapy in patients with breakthrough symptoms.
[So] Source:Aliment Pharmacol Ther;45(12):1524-1533, 2017 06.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Symptomatic breakthrough in proton pump inhibitor (PPI)-treated gastro-oesophageal reflux disease (GERD) patients is a common problem with a range of underlying causes. The nonsystemic, raft-forming action of alginates may help resolve symptoms. AIM: To assess alginate-antacid (Gaviscon Double Action, RB, Slough, UK) as add-on therapy to once-daily PPI for suppression of breakthrough reflux symptoms. METHODS: In two randomised, double-blind studies (exploratory, n=52; confirmatory, n=262), patients taking standard-dose PPI who had breakthrough symptoms, assessed by Heartburn Reflux Dyspepsia Questionnaire (HRDQ), were randomised to add-on Gaviscon or placebo (20 mL after meals and bedtime). The exploratory study endpoint was change in HRDQ score during treatment vs run-in. The confirmatory study endpoint was "response" defined as ≥3 days reduction in the number of "bad" days (HRDQ [heartburn/regurgitation] >0.70) during treatment vs run-in. RESULTS: In the exploratory study, significantly greater reductions in HRDQ scores (heartburn/regurgitation) were observed in the Gaviscon vs placebo (least squares mean difference [95% CI] -2.10 [-3.71 to -0.48]; P=.012). Post hoc "responder" analysis of the exploratory study also revealed significantly more Gaviscon patients (75%) achieved ≥3 days reduction in "bad" days vs placebo patients (36%), P=.005. In the confirmatory study, symptomatic improvement was observed with add-on Gaviscon (51%) but there was no significant difference in response vs placebo (48%) (OR (95% CI) 1.15 (0.69-1.91), P=.5939). CONCLUSIONS: Adding Gaviscon to PPI reduced breakthrough GERD symptoms but a nearly equal response was observed for placebo. Response to intervention may vary according to whether symptoms are functional in origin.
[Mh] Termos MeSH primário: Alginatos/administração & dosagem
Hidróxido de Alumínio/administração & dosagem
Antiácidos/administração & dosagem
Dor Irruptiva/tratamento farmacológico
Refluxo Gastroesofágico/tratamento farmacológico
Inibidores da Bomba de Prótons/administração & dosagem
Ácido Silícico/administração & dosagem
Bicarbonato de Sódio/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Alginatos/efeitos adversos
Hidróxido de Alumínio/efeitos adversos
Antiácidos/efeitos adversos
Antiulcerosos/administração & dosagem
Antiulcerosos/efeitos adversos
Método Duplo-Cego
Combinação de Medicamentos
Feminino
Azia/tratamento farmacológico
Seres Humanos
Masculino
Meia-Idade
Inibidores da Bomba de Prótons/efeitos adversos
Ácido Silícico/efeitos adversos
Bicarbonato de Sódio/efeitos adversos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Alginates); 0 (Antacids); 0 (Anti-Ulcer Agents); 0 (Drug Combinations); 0 (Proton Pump Inhibitors); 1343-98-2 (Silicic Acid); 5QB0T2IUN0 (Aluminum Hydroxide); 66220-44-8 (alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination); 8MDF5V39QO (Sodium Bicarbonate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1111/apt.14064


  7 / 3321 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29031441
[Au] Autor:Xiao G; Zeng H; Xu S; Chen C; Zhao Q; Liu X
[Ad] Endereço:College of Chemical Engineering, Xiangtan University, Xiangtan 411105, Hunan, China. Electronic address: mgaofei@foxmail.com.
[Ti] Título:Preparation of Ti species coating hydrotalcite by chemical vapor deposition for photodegradation of azo dye.
[So] Source:J Environ Sci (China);60:14-23, 2017 Oct.
[Is] ISSN:1001-0742
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:TiO in anatase crystal phase is a very effective catalyst in the photocatalytic oxidation of organic compounds in water. To improve its photocatalytic activity, the Ti-coating MgAl hydrotalcite (Ti-MgAl-LDH) was prepared by chemical vapor deposition (CVD) method. Response surface method (RSM) was employed to evaluate the effect of Ti species coating parameters on the photocatalytic activity, which was found to be affected by the furnace temperature, N flow rate and influx time of precursor gas. Application of RSM successfully increased the photocatalytic efficiency of the Ti-MgAl-LDH in methylene blue photodegradation under UV irradiation, leading to improved economy of the process. According to the results from X-ray diffraction, scanning electron microscopy, Brunner-Emmet-Teller and Barrett-Joyner-Hallender, thermogravimetric and differential thermal analysis, UV-vis diffuse reflectance spectra analyses, the Ti species (TiO or/and Ti ) were successfully coated on the MgAl-LDH matrix. The Ti species on the surface of the Ti-MgAl-LDH lead to a higher photocatalytic performance than commercial TiO -P25. The results suggested that CVD method provided a new approach for the industrial preparation of Ti-coating MgAl-LDH material with good photocatalytic performances.
[Mh] Termos MeSH primário: Hidróxido de Alumínio/química
Compostos Azo/química
Hidróxido de Magnésio/química
Eliminação de Resíduos Líquidos/métodos
[Mh] Termos MeSH secundário: Corantes/química
Fotólise
Titânio
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Azo Compounds); 0 (Coloring Agents); 15FIX9V2JP (titanium dioxide); 17432CG1KU (hydrotalcite); 5QB0T2IUN0 (Aluminum Hydroxide); D1JT611TNE (Titanium); NBZ3QY004S (Magnesium Hydroxide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171017
[St] Status:MEDLINE


  8 / 3321 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28700956
[Au] Autor:Guo J; Chen C
[Ad] Endereço:College of Resources and Environment, Chengdu University of Information Technology, Chengdu, Sichuan, 610225, China. Electronic address: gjy@cuit.edu.cn.
[Ti] Título:Sludge conditioning using the composite of a bioflocculant and PAC for enhancement in dewaterability.
[So] Source:Chemosphere;185:277-283, 2017 Oct.
[Is] ISSN:1879-1298
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This study investigated the production of a bioflocculant by using rice stover and its potential in sludge dewatering. Production of the bioflocculant was positively associated with cell growth and highest value of 2.37 g L was obtained with main backbone of polysaccharides. The bioflocculant showed good performances in sludge dewatering, after conditioned by this bioflocculant, dry solids (DS) and specific resistance to filtration (SRF) of typical wastewater activated sludge reached 19.3% and 4.8 × 10 m kg , respectively, which were much better than the ones obtained with chemical flocculants. Sludge dewatering was further improved when the bioflocculant and polyaluminum chloride (PAC) were used simultaneously, and the optimized conditioning process by the composite was bioflocculant of 10.5 g kg , PAC of 19.4 g kg , and pH of 8.1. Under this optimal condition, DS and SRF of the sludge appeared as 24.1% and 3.0 × 10 m kg , respectively.
[Mh] Termos MeSH primário: Dessecação/métodos
Floculação
Esgotos/química
[Mh] Termos MeSH secundário: Hidróxido de Alumínio/farmacologia
Filtração
Concentração de Íons de Hidrogênio
Oryza/química
Águas Residuais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sewage); 0 (Waste Water); 1327-41-9 (aluminum oxychloride); 5QB0T2IUN0 (Aluminum Hydroxide)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE


  9 / 3321 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28647236
[Au] Autor:Zhang Z; Wang J; Liu D; Li J; Wang X; Song B; Yue B; Zhao K; Song Y
[Ad] Endereço:Key Laboratory of Energy-Water Conservation and Wastewater Resources Recovery (Environmental Protection Research Institute of Light Industry), China National Light Industry, Beijing 100089, China. Electronic address: cn.zhang@163.com.
[Ti] Título:Hydrolysis of polyaluminum chloride prior to coagulation: Effects on coagulation behavior and implications for improving coagulation performance.
[So] Source:J Environ Sci (China);57:162-169, 2017 Jul.
[Is] ISSN:1001-0742
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The effects of polyaluminum chloride (PACl) hydrolysis prior to coagulation on both the coagulation zone and coagulation performance of a kaolin suspension were investigated by a novel jar test named the "reversed coagulation test". The tests showed that PACl hydrolysis prior to coagulation decreased the performance of charge neutralization coagulation in the case of short-time slow mixing (10min; G=15sec ) and increased the optimal dosage for charge neutralization and sweep coagulation. Moreover, the hydrolysis time had insignificant effects on the size and zeta potential of PACl precipitates and the residual turbidity of the raw water. However, PACl hydrolysis prior to coagulation and the size of PACl precipitates had a negligible effect on the performance of sweep coagulation. The results imply that, in practice, preparing a PACl solution with deionized water, rather than tap water or the outlet water from a wastewater treatment unit, can significantly save PACl consumption and improve the performance of charge neutralization coagulation, while preparing the PACl solution with tap or outlet water would not affect the performance of sweep coagulation. In addition, the optimal rapid mixing intensity appears to be determined by a balance between the degree of coagulant hydrolysis before contacting the primary particles and the average size of flocs in the rapid mixing period. These results provide new insights into the role of PACl hydrolysis and will be useful for improving coagulation efficiency.
[Mh] Termos MeSH primário: Hidróxido de Alumínio/química
Purificação da Água/métodos
[Mh] Termos MeSH secundário: Floculação
Hidrólise
Caulim
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
1327-41-9 (aluminum oxychloride); 24H4NWX5CO (Kaolin); 5QB0T2IUN0 (Aluminum Hydroxide)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170714
[Lr] Data última revisão:
170714
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170626
[St] Status:MEDLINE


  10 / 3321 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28591778
[Au] Autor:Huang LM; Puthanakit T; Cheng-Hsun C; Ren-Bin T; Schwarz T; Pellegrino A; Esposito S; Frenette L; McNeil S; Durando P; Rheault P; Giaquinto C; Horn M; Petry KU; Peters K; Azhar T; Hillemanns P; De Simoni S; Friel D; Pemmaraju S; Hezareh M; Thomas F; Descamps D; Folschweiller N; Struyf F
[Ad] Endereço:Department of Pediatrics, National Taiwan University Children's Hospital, National Taiwan University, Taipei.
[Ti] Título:Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.
[So] Source:J Infect Dis;215(11):1711-1719, 2017 Jun 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: We previously reported the noninferiority 1 month after the last dose of 2-dose human papillomavirus 16/18 AS04-adjuvanted (AS04-HPV-16/18) vaccine schedules at months 0 and 6 (2D_M0,6) and months 0 and 12 (2D_M0,12) in girls aged 9-14 years compared with a 3-dose schedule at months 0, 1, and 6 (3D_M0,1,6) in women aged 15-25 years. Here, we report the results at study end (month 36 [M36]). Methods: Girls were randomized 1:1 and received 2 vaccine doses either 6 months (2D_M0,6) or 12 months apart (2D_M0,12); women received 3 doses at months 0, 1, and 6 (3D_M0,1,6). Endpoints included noninferiority of HPV-16/18 antibodies for 2D_M0,6 versus 3D_M0,1,6; 2D_M0,12 versus 3D_M0,1,6; and 2D_M0,12 versus 2D_M0,6; and assessment of neutralizing antibodies, T cells, B cells, and safety. Results: At M36, the 2D_M0,6 and 2D_M0,12 schedules remained noninferior to the 3D_M0,1,6 schedule in terms of seroconversion rates and 3D/2D geometric mean titers for anti-HPV-16 and anti-HPV-18. All schedules elicited sustained immune responses up to M36. Conclusions: Both 2-dose schedules in young girls remained noninferior to the 3-dose schedule in women up to study conclusion at M36. The AS04-HPV-16/18 vaccine administered as a 2-dose schedule was immunogenic and well tolerated in young girls.
[Mh] Termos MeSH primário: Papillomavirus Humano 16/imunologia
Papillomavirus Humano 18/imunologia
Vacinas contra Papillomavirus/administração & dosagem
Vacinas contra Papillomavirus/imunologia
[Mh] Termos MeSH secundário: Adolescente
Hidróxido de Alumínio
Anticorpos Antivirais/sangue
Criança
Feminino
Seres Humanos
Lipídeo A/análogos & derivados
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (ASO4 mixture); 0 (Antibodies, Viral); 0 (Lipid A); 0 (Papillomavirus Vaccines); 0 (human papillomavirus vaccine, L1 type 16, 18); 5QB0T2IUN0 (Aluminum Hydroxide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix154



página 1 de 333 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde